Karyopharm Therapeutics Inc (KPTI) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Karyopharm Therapeutics Inc stock (KPTI) is currently trading at $5.21. Karyopharm Therapeutics Inc PS ratio (Price-to-Sales) is 0.84. Analyst consensus price target for KPTI is $15.33. WallStSmart rates KPTI as Sell.
- KPTI PE ratio analysis and historical PE chart
- KPTI PS ratio (Price-to-Sales) history and trend
- KPTI intrinsic value — DCF, Graham Number, EPV models
- KPTI stock price prediction 2025 2026 2027 2028 2029 2030
- KPTI fair value vs current price
- KPTI insider transactions and insider buying
- Is KPTI undervalued or overvalued?
- Karyopharm Therapeutics Inc financial analysis — revenue, earnings, cash flow
- KPTI Piotroski F-Score and Altman Z-Score
- KPTI analyst price target and Smart Rating
Karyopharm Therapeutics Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Karyopharm Therapeutics Inc (KPTI) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, institutional own.. Concerns around market cap and peg ratio. Significant fundamental concerns warrant caution or avoidance.
Karyopharm Therapeutics Inc (KPTI) Key Strengths (2)
Paying less than $1 for every $1 of annual revenue
53.04% held by institutions, strong professional interest
Supporting Valuation Data
Karyopharm Therapeutics Inc (KPTI) Areas to Watch (7)
PEG ratio is negative or unavailable
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Very expensive at 12.1x book value
Micro-cap company with very limited liquidity and high volatility
Solid revenue growth at 11.60% per year
Karyopharm Therapeutics Inc (KPTI) Detailed Analysis Report
Overall Assessment
This company scores 29/100 in our Smart Analysis, earning a F grade. Out of 9 metrics analyzed, 2 register as strengths (avg 9.0/10) while 7 fall into concern territory (avg 1.6/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Sales, Institutional Own.. Valuation metrics including Price/Sales (0.84) suggest the stock is attractively priced.
The Bear Case
The primary concerns are PEG Ratio, Return on Equity, Operating Margin. Some valuation metrics including PEG Ratio (N/A), Price/Book (12.05) suggest expensive pricing. Growth concerns include Revenue Growth at 11.60%, which may limit upside. Profitability pressure is visible in Return on Equity at -891.00%, Operating Margin at -52.40%, Profit Margin at -134.20%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether PEG Ratio improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -891.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 11.60% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. PEG Ratio and Return on Equity are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
KPTI Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
KPTI's Price-to-Sales ratio of 0.84x trades at a deep discount to its historical average of 430.19x (30th percentile). The current valuation is 100% below its historical high of 2522.5x set in Apr 2015, and 945% above its historical low of 0.08x in Jan 2025. Over the past 12 months, the PS ratio has expanded from ~0.5x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Karyopharm Therapeutics Inc (KPTI) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Karyopharm Therapeutics Inc is in a turnaround phase, with management focused on restoring profitability. Revenue reached 146M with 12% growth year-over-year. The company is currently unprofitable, posting a -134.2% profit margin.
Key Findings
Spending 19% of revenue (28M) on R&D, reinforcing its commitment to innovation and future growth.
The company is unprofitable with a -134.2% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -12M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Karyopharm Therapeutics Inc.
Bottom Line
Karyopharm Therapeutics Inc is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Karyopharm Therapeutics Inc(KPTI)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Karyopharm Therapeutics Inc., a pharmaceutical company, is dedicated to the discovery, development and commercialization of various drugs directed against nuclear export and related targets for the treatment of cancer and other diseases. The company is headquartered in Newton, Massachusetts.